肝癌肝移植全过程管理及治疗进展

外科理论与实践››2022,Vol. 27››Issue (02): 119-122.doi:10.16139/j.1007-9610.2022.02.006

肝癌肝移植全过程管理及治疗进展

冯浩¹^,²^,³, 吕子成¹, 夏强¹^,²^,³()

1.开云网页登录医学院附属仁济医院肝脏外科,上海 200127
2.上海市器官移植研究所,上海 200127
3.上海市器官移植与免疫工程技术研究中心,上海 200127

收稿日期:2022-01-25出版日期:2022-05-25发布日期:2022-06-16
通讯作者:夏强 E-mail:xiaqiang@medmail.com.cn
基金资助:
上海市申康中心临床科技创新项目“普外科专科联盟”;国家自然科学基金(81972205);国家自然科学基金重大研究计划(92059205);上海申康医院发展中心三年行动计划关键支撑项目(SHDC2020CR5012)

Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment

FENG Hao¹^,²^,³, LÜ Zicheng¹, XIA Qiang¹^,²^,³()

Received:2022-01-25Online:2022-05-25Published:2022-06-16
Contact:XIA Qiang E-mail:xiaqiang@medmail.com.cn

摘要/Abstract

中图分类号:

冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.

FENG Hao, LÜ Zicheng, XIA Qiang. Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122.

参考文献21

[1]	Kardashian A, Florman SS, Haydel B, et al. Liver transplantation outcomes in a U.S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria[J]. Hepatology, 2020, 72(6):2014-2028. doi:10.1002/hep.31210 URL
[2]	Ziogas IA, Giannis D, Economopoulos KP, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates[J]. Transplantation, 2021, 105(10):2263-2271. doi:10.1097/TP.0000000000003539 URL
[3]	Giannis D, Sideris G, Kakos CD, et al. The role of liver transplantation for colorectal liver metastases: a systema-tic review and pooled analysis[J]. Transplant Rev (Orlando), 2020, 34(4):100570.
[4]	Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review[J]. Surgery, 2017, 162(3):525-536. doi:10.1016/j.surg.2017.05.006 URL
[5]	Sapisochin G, Hibi T, Toso C, et al. Transplant oncology in primary and metastatic liver tumor: principles, evidence and opportunities[J]. Ann Surg, 2021, 73(3):483-493.
[6]	冯浩, 夏强. 肝移植与肿瘤:发展、机遇与挑战[J]. 中华器官移植杂志, 2021, 42(2):65-67.
[7]	Benson AB, D′Angelica MI, Abbott DE, et al. Hepatobi-liary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565. doi:10.6004/jnccn.2021.0022 URL
[8]	Jia AY, Popovic A, Mohan AA, et al. Development, practice patterns, and early clinical outcomes of a multidisciplinary liver cancer clinic[J]. Cancer Control, 2021, 28:10732748211009945.
[9]	张子杰, 乔子耘, 冯浩, 等. 系统治疗在肝癌术前新辅助治疗中应用进展[J]. 中国实用外科杂志, 2021, 41(3):326-331.
[10]	Kardashian A, Florman SS, Haydel B, et al. Liver transplantation outcomes in a US multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria[J]. Hepatology, 2020, 72(6):2014-2028. doi:10.1002/hep.31210 URL
[11]	Cambridge WA, Fairfield C, Powell JJ, et al. Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Ann Surg, 2021, 273(2):240-250. doi:10.1097/SLA.0000000000003801 URL
[12]	Potter W, Davidi S, Jacobovitch S, et al. Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo[J]. J Clin Oncol, 2022, 40(4 suppl):464-464.
[13]	Zhang YF, Guo RP, Zou RH, et al. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study[J]. Eur Radiol, 2016, 26(7):2078-2088. doi:10.1007/s00330-015-4021-8 URL
[14]	Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation[J]. Hepatology, 2007, 45(2):269-276. doi:10.1002/hep.21465 URL
[15]	Han B, Ding H, Zhao S, et al. Potential role of adjuvant lenvatinib in improving disease-free survival for patients with high-risk hepatitis B virus-related hepatocellular carcinoma following liver transplantation: a retrospective, case control study[J]. Front Oncol, 2020, 10:562103.
[16]	Chen YY, Chen CL, Lin CC, et al. Efficacy and safety of lenvatinib in hepatocellular carcinoma patients with liver transplantation: a case-control study[J]. Cancers (Basel), 2021, 13(18):4584. doi:10.3390/cancers13184584 URL
[17]	European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. doi:10.1016/j.jhep.2018.03.019 URL
[18]	Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation[J]. J Vasc Interv Radiol, 2010, 21(3):333-338. doi:10.1016/j.jvir.2009.11.006pmid:20116286
[19]	Ko HK, Ko GY, Yoon HK, et al. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation[J]. Korean J Radiol, 2007, 8(4):320-327. doi:10.3348/kjr.2007.8.4.320 URL
[20]	Au KP, Chiang CL, Chan ACY, et al. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation[J]. World J Clin Cases, 2020, 8(13):2758-2768. doi:10.12998/wjcc.v8.i13.2758 URL
[21]	Walburn T, Moon AM, Hayashi PH, et al. Stereotactic body radiation therapy for recurrent, isolated hepatocellular carcinoma lymph node metastasis with or without prior liver transplantation[J]. Cureus, 2020, 12(8):e9988.

肝癌肝移植全过程管理及治疗进展

Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献21

相关文章15

编辑推荐

Metrics

本文评价

[1]	刘文韬, 刘福坤.中国胃癌围术期综合治疗概述与展望[J]. 外科理论与实践, 2023, 28(01): 36-41.
[2]	任新平, 李军建, 张杰, 詹维伟.超声造影在肝局灶性病变诊疗中的应用进展[J]. 诊断学理论与实践, 2022, 21(06): 684-690.
[3]	杨雪, 刘锦, 王铮, 陶杰, 郝杰, 李宇, 孙昊.他克莫司降低肝移植病人ERCP术后胰腺炎发生的临床观察[J]. 外科理论与实践, 2022, 27(03): 253-255.
[4]	马婧嶔, 杨敏捷, 颜志平.精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022, 27(02): 131-133.
[5]	孙惠川.肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138.
[6]	吴浩翔, 吕子成, 侯宇宸, 张子杰, 乔子耘, 冯浩, 夏强.儿童肝移植中他克莫司浓度个体内变异[J]. 外科理论与实践, 2022, 27(02): 145-151.
[7]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜.肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[8]	张磊, 毛家玺, 李涛, 滕飞, 孙克彦.术前免疫炎症反应对原发性胆汁性胆管炎肝移植病人预后影响的双中心回顾性研究[J]. 外科理论与实践, 2022, 27(02): 158-164.
[9]	管涛(综述), 张倜, 王鲁(审校).肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184.
[10]	黄纪伟, 邱国腾, 曾勇.肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[11]	苏长青.从基础研究到临床转化应用谈肝癌的诊治进展[J]. 诊断学理论与实践, 2021, 20(05): 427-433.
[12]	李涛, 陈皓.肝硬化门静脉高压症的肝移植治疗[J]. 外科理论与实践, 2021, 26(03): 189-194.
[13]	戚德彬, 陈鹏, 佟辉, 彭承宏, 李涛.肝移植术后撤除免疫抑制剂的回顾性分析[J]. 外科理论与实践, 2021, 26(03): 231-235.
[14]	吴城孝, 方婕, 周霁川, 肖永胜, 张晓光.基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析[J]. 外科理论与实践, 2021, 26(03): 249-253.
[15]	梅郁, 朱正纲.胃印戒细胞癌的临床病理特征与外科综合治疗[J]. 外科理论与实践, 2021, 26(01): 79-83.